Europe - EPA:ALERS - FR0013240934 - Common Stock
We assign a fundamental rating of 6 out of 10 to ALERS. ALERS was compared to 73 industry peers in the Biotechnology industry. ALERS gets an excellent profitability rating and is at the same time showing great financial health properties. ALERS is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, ALERS could be worth investigating further for growth and quality investing!.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 1.55% | ||
ROE | 2.24% | ||
ROIC | 4.25% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 8.81% | ||
PM (TTM) | 2.59% | ||
GM | 46.49% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.17 | ||
Debt/FCF | 2.53 | ||
Altman-Z | 3.84 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.03 | ||
Quick Ratio | 1.42 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 96.92 | ||
Fwd PE | 15.29 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 19.21 | ||
EV/EBITDA | 8.9 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
EPA:ALERS (10/6/2025, 7:00:00 PM)
25.2
-0.35 (-1.37%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 96.92 | ||
Fwd PE | 15.29 | ||
P/S | 1.67 | ||
P/FCF | 19.21 | ||
P/OCF | 15.46 | ||
P/B | 1.45 | ||
P/tB | 10.26 | ||
EV/EBITDA | 8.9 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 1.55% | ||
ROE | 2.24% | ||
ROCE | 6.39% | ||
ROIC | 4.25% | ||
ROICexc | 4.76% | ||
ROICexgc | 24.83% | ||
OM | 8.81% | ||
PM (TTM) | 2.59% | ||
GM | 46.49% | ||
FCFM | 8.7% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.17 | ||
Debt/FCF | 2.53 | ||
Debt/EBITDA | 1.02 | ||
Cap/Depr | 19.09% | ||
Cap/Sales | 2.11% | ||
Interest Coverage | 250 | ||
Cash Conversion | 54.46% | ||
Profit Quality | 336.34% | ||
Current Ratio | 2.03 | ||
Quick Ratio | 1.42 | ||
Altman-Z | 3.84 |